Abstract The finding of TDP-43 as a major component of ubiquitinated protein inclusions in amyotrophic lateral sclerosis (ALS) has led to the identification of 30 mutations in the transactive response-DNA binding protein (TARDBP) gene, encoding TDP-43. All but one are in exon 6, which encodes the glycine-rich domain. The aim of this study was to determine the frequency of TARDBP mutations in a large cohort of motor neurone disease patients from Northern England (42 non-superoxide dismutase 1 (SOD1) familial ALS (FALS), nine ALS-frontotemporal dementia, 474 sporadic ALS (SALS), 45 progressive muscular atrophy cases). We identified four mutations, two of which were novel, in two familial (FALS) and two sporadic (SALS) cases, giving a frequency of TARDBP mutations in non-SOD1 FALS of 5% and SALS of 0.4%. Analysis of clinical data identified that patients had typical ALS, with limb or bulbar onset, and showed considerable variation in age of onset and rapidity of disease course. However, all cases had an absence of clinically overt cognitive dysfunction.
Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most common adult-onset, neurodegenerative diseases, characterised by progressive cell death of motor neurones (MNs) in the motor cortex, brainstem and spinal cord. Whilst the majority of cases are sporadic (sporadic ALS, SALS), a familial component is present in 5-10% (familial ALS, FALS) and is usually associated with an autosomaldominant mode of inheritance. To date, the most common cause of FALS is mutation of the superoxide dismutase 1 (SOD1) gene, although this only accounts for 20% of FALS cases [1] . Although other autosomal-dominant loci have been identified [2] , so far, mutations in the two genes senataxin and vesicle-associated membrane proteinassociated protein B have not been found to be a common cause of ALS in large cohorts [3] . In contrast, SOD1 mutations have been found worldwide both in FALS and in apparent SALS cases [4] .
Approximately 3% to 10% of patients with ALS also show signs of frontotemporal dementia (FTD), whilst detailed neuropsychological evaluation reveals that up to 50% of ALS cases have evidence of cognitive impairment [5] [6] [7] [8] . Studies of cases with ALS + dementia + Parkinson's disease have revealed mutations in the MAPT gene, encoding the microtubule associated protein tau. In addition, two loci on chromosome 9, 9p12-p21 [9, 10] and Authors Janine Kirby and Emily F. Goodall made an equal contribution. 9q21-q22 [11] , have been identified through genetic linkage studies to harbour genes responsible for ALS + FTD.
Neuropathological examination of both ALS and FTD cases has shown the presence of neuronal cytoplasmic inclusions, which stain positive for ubiquitin but negative for tau and α-synuclein. Neumann and colleagues demonstrated that a major protein component of these inclusions was transactive response (TAR)-DNA binding protein (TARDBP; TDP-43) [12] . TDP-43, a ubiquitously expressed nuclear protein, was originally identified as a protein that binds the TAR region of DNA of HIV-1 [13] . In addition to acting as both a transcriptional repressor and an activator of exon skipping [14] , it also reportedly plays a role as a scaffold protein for nuclear bodies, through interaction with survival MN protein [15] . A further functional role for TDP-43 in MNs may be the stabilisation of neurofilament light (NFL) mRNA by direct binding of TDP-43 to the 3′ untranslated region (UTR) of NFL [16] .
Mackenzie and colleagues, investigating TDP-43 pathology in a cohort of 111 ALS cases, demonstrated that TDP-43 pathology was associated with SALS, FALS (without SOD1 mutation) and ALS + FTD, but not with SOD1-related FALS [17] . This was followed by several screening studies where mutations and linkage of ALS was not found associated with the TARDBP gene, which encodes the TDP-43 protein [18, 19] . However, Sreedharan and colleagues identified mutations in exon 6 of TARDBP in two familial and two sporadic cases [20] . This was supported by further studies identifying mutations in exon 6 in both familial and sporadic disease [21] [22] [23] [24] [25] . The aim of the present study was to determine the frequency of TARDBP mutations in our large cohort of MN disease (MND) patients from the north of England and to establish the clinical phenotype associated with these mutations.
Materials and methods
The Sheffield MND Blood DNA Bank contains DNA extracted from 37 FALS, eight ALS-FTD, 407 SALS and 34 progressive muscular atrophy (PMA) cases. Additional DNA samples were isolated from five non-SOD1 FALS, one ALS-FTD, 67 SALS and 11 PMA cases identified in the Sheffield Brain Tissue Bank, providing a cohort of 42 non-SOD1 FALS, nine ALS-FTD, 474 SALS and 45 PMA cases. ALS patients had definite or probable ALS as defined by the El Escorial criteria. Cases with SOD1 mutations were excluded from the analysis. DNA was extracted from blood using the Nucleon Blood and Cell Culture Genomic Extraction kit (Tepnel, UK) according to the manufacturer's protocol, whilst DNA was extracted from fresh frozen cerebellar samples using the Soft Tissue DNA Extraction Kit (Tepnel, UK). Control DNA (n=183) was extracted from blood donated by partners or unrelated carers of MND patients. Additional controls were obtained from the Birmingham MND DNA bank (n=316). All samples were from UK Caucasians. The South Sheffield Research Ethics Committee approved the study, and informed consent has been obtained for all cases.
The TARDBP gene comprises of six exons of which the first exon is non-coding [24] . Primers were designed to amplify the six exons (Ensembl transcript ID: ENST00000240185) as well as the intron/exon boundaries (Table 1) . Polymerase chain reaction (PCR) products were treated with ExoSAP-IT (GE Healthcare) before bidirectional sequencing using BigDye Terminator v3.1 (ABI) according to the manufacturer's protocol. The resulting reactions were electrophoresed on a DNA Analyser 3730 capillary sequencer (ABI). The chromatographs were analysed by Sequencher (Gene Codes Corporation, USA) and any potential mutations validated by sequencing a second PCR reaction.
To screen for the presence of the exon 6 nucleotide changes in the general population, 499 neurologically normal age-matched Caucasian controls were bidirectionally sequenced as described above. Control DNA samples (n=183) were also bi-directionally sequenced to screen for the exon 3 nucleotide change.
To establish the effect of the identified TARDBP mutations, quantitative PCR (QPCR) of cyclin-dependent kinase 6 (CDK6) was performed on fibroblasts derived from patients carrying TARDBP mutations. RNA was extracted from three mutant TARDBP fibroblasts (p. G287S, p.A321V, p.M337V) and six control fibroblast cultures using the RNeasy Mini Kit, according to manufacturer's protocol (Qiagen). Following cDNA synthesis using Superscript II (Invitrogen), QPCR was used to determine the expression levels of CDK6 (Assay ID Hs01026372_m1, Applied Biosystems) in each of the samples. ACTB (Applied Biosystems) was used as the endogenous control. Reactions were run on an MX3000 (Stratagene), and data were analysed using MX Pro. An unpaired t test was used to establish if CDK6 expression levels were significantly different to controls.
Results
Mutation screening of the six exons of the TARDBP gene, including intron/exon boundaries, in 42 FALS, nine ALS-FTD, 474 SALS and 45 PMA cases identified four mutations in exon 6, of which two were novel. In addition, we identified two novel SNPs in the 5′ UTR, three novel synonymous SNPs, one previously published synonymous SNP in the coding region and three intronic substitutions. A further non-synonymous change was found in a patient and a control ( Table 2) .
The four TARDBP mutations were found in two FALS cases and two SALS cases. In the first family (FALS1), the index case showed a c.1009A>G substitution leading to p. Met377Val (Fig. 1a) . Screening of family members showed that the sister of the index case, who is also affected with ALS, carries the mutation, whilst an unaffected brother was homozygous for the wild-type allele (Fig. 1b) . In the second family (FALS2), a c.1043G>T substitution was found in the index case, leading to a p.Gly348Val amino acid change (Fig. 2a) . Screening of a brother, who was also affected with the disease, showed that he also carried the mutation (Fig. 2b) . The two mutations found in SALS cases were a c.859G>A substitution which results in a p.Gly287Ser amino acid alteration (SALS1) and a c.962C>T which leads to a p. Ala321Val substitution (SALS2; Fig. 3 ). None of these four mutations were found in 499 neurologically normal controls.
In addition, in a third SALS case (SALS3), an exon 3 c.269C>T substitution was identified, which encodes the amino acid alteration p.Ala90Val. Screening of controls also identified this mutation in a male aged 78 years at time of donation. Since it has also been published previously in controls, this substitution is likely to represent a nonpathogenic polymorphism [18, 20, 21] . Novel synonymous SNPs were identified in three SALS cases in exon 2 (p. Leu27), exon 3 (p.Ser104) and exon 4 (p.Lys137), along with two SALS cases carrying the previously reported p.Ala66 SNP in exon 2 [18, 21, 23, [26] [27] [28] .
Functional implications of the mutations
The five amino acid substitutions were run through several databases to predict the effects of the alteration on the structure and function of the protein (Table 3 ). The two FALS mutations p.M337V and p.G348V and the novel SALS mutation p.A321V are all predicted to be pathological according to PMut, and the two FALS mutations are also likely to be damaging, according to PolyPhen. In contrast, the G287S substitution found in SALS1 is listed as benign by PolyPhen and neutral by PMut, as is the A90V variant, found in both a case and control.
In order to establish the functional implications of the TARDBP mutations in vivo, we obtained fibroblast cultures from three ALS patients, carrying the p.G287S, p.A321V and p.M337V. TDP-43 has been shown to repress the expression of CDK6, via GT repeats in the CDK6 sequence [29] . QPCR showed that CDK6 transcript levels were increased in the mutant TARDBP fibroblast samples, compared to levels in controls (Fig. 4) , suggesting that the three mutant TDP-43 proteins were unable to repress CDK6.
Clinical phenotypes
These are summarised in Table 4 .
FALS1
The index case (II.1) developed mild dysarthria at the age of 57 years. Subsequently, he went on to develop a mild distal weakness with loss of dexterity in the left hand and painless left foot drop. The signs were of a classical ALS phenotype with mixed upper and lower motor signs in the bulbar and limb regions. Disease progression has been slow, and 48 months since the onset of symptoms, the individual remains ambulant with assistance, manages an oral diet with consistency changes and is free from respiratory symptoms. The ALS functional rating scale score at his last visit was 32/40. Forced vital capacity measurements are unreliable due to his bulbar disease, but daytime pCO 2 measurements are normal (Fig. 1) .
A sister (II.2) at 42 years old developed progressive weakness of the right hand. Within 3 years, the individual had similar problems in the left arm and had developed a spastic dysarthria and mild dysphagia. Seven years into the illness, the lower limbs were affected with slow walking only possible over short distances. Nine years after onset of symptoms, the individual was effectively wheelchair-bound A brother (II.4) developed ALS at the age of 31 and experienced rapid disease progression, dying only 9 months after the onset of symptoms. The daughter of II.4, III.1, has a progressive neurodegenerative disorder affecting the pyramidal and cerebellar systems. III.1 was born by ventouse extraction at term after a normal pregnancy and initially achieved normal milestones, walking by 11 months. However, by the age of 2.5 years, language and intellectual impairment was apparent. Her walking deteriorated over a decade until she was largely confined to a wheelchair. In addition, at the age of 12 years, she developed generalised seizures. The major features on examination were a spastic tetraparesis with relatively preserved power, a concomitant convergent strabismus and intellectual impairment. Investigations revealed an atrophic cerebellum on MRI scan, with other investigations normal, including nerve conduction studies, electromyography (EMG), lysosomal enzymes, genetic screening of SCA 1-3, SCA 6, SCA 7, frataxin and dentatorubropallidoluysian atrophy. The mother (I.2) of the index case developed progressive loss of voice and limb weakness due to MND at the age of 55 and died of the illness 6 years later. A further brother (II.3), who does not carry the p.M337V mutation, is healthy at the age of 51, with no evidence of ALS.
FALS2
The index case (II.1) developed painless left foot drop when 51 years old. Weakness progressed to the left leg and right arm before becoming generalised involving respiratory muscles. Bulbar function remained relatively intact throughout the (Fig. 2) . The younger brother (II.2) developed progressive weakness of the right upper limb at 57 years of age. The weakness progressed bilaterally resembling a flail arm phenotype of MND, before becoming generalised, affecting all limbs and respiratory muscles. Upper MN involvement and bulbar dysfunction were again minimal. Thirty-six months after symptom onset, the individual died from respiratory failure.
In the preceding generation, the mother (I.2) had died from MND at the age of 65 years. A maternal aunt (1.3) and uncle (1.4) were reported to have died from muscular atrophy in their 40s. No further information was available on these cases.
SALS1
This individual presented at the age of 52 years with a 2-year progressive history of clumsiness of the left hand and left leg. At presentation, the individual had mixed upper and lower signs in the left upper and lower limbs with dysarthria and a weak fasciculating tongue. The disease in this individual has run a relatively indolent course, and 6 years following symptom onset, bulbar symptoms remain mild, and there is no evidence of respiratory insufficiency. Limb weakness has progressed with some help required with activities of daily living such as dressing, and a wheelchair is necessary for travelling outside the home. There is no known family history of neurological disease.
SALS2
This individual developed progressive weakness and loss of dexterity of the left hand at the age of 38 years. On examination, there were mixed upper and lower MN signs in the left upper limb. EMG demonstrated more widespread denervation consistent with a diagnosis of ALS, and investigation, including imaging of the neuroaxis, has not identified an alternative cause. The individual, 2 years following the onset of symptoms, is experiencing increas- ing weakness of the left hand and fatigue but no other major problems, particularly no dysarthria, dysphagia or leg weakness. There is no family history of neuromuscular disorder. Her mother died at the age of 44 years and father at 62 years both due to malignancy. Two siblings are healthy at the ages of 37 and 41 years.
It should be noted that the mutations were all found in DNA from the Sheffield MND Blood DNA Bank, rather than the Sheffield Brain Tissue Bank. Therefore, no neuropathological investigation has been possible in these cases.
Discussion
Screening of a large cohort of MND cases including 42 FALS and 474 SALS has identified four mutations in exon 6 of the TARDBP gene, the p.Gly287Ser and p.Ala321Val in two SALS cases and the p.Met337Val and p.Gly348Val in two FALS cases. This suggests a frequency for TARDBP mutations in northern England of 5% for FALS and 0.4% for SALS. Three novel synonymous substitutions were also identified in cases of SALS, p.Leu27, p.Ser104 and p.
Lys137. An additional non-synonymous substitution p. Ala90Val, which has previously been found in controls [20, 21] , was also found in a SALS case. Although it is predicted to have no effect on protein function, in vitro studies have shown mis-localisation of this protein [30] .
Broad clinical ALS phenotypes are associated with TARDBP mutations
The clinical phenotype encompasses patients with bulbar, limb and respiratory onset disease and with short and long disease durations. All our patients had clinical features in keeping with ALS, and no mutations were found in patients with a pure lower MN clinical phenotype (PMA). It is noteworthy that, despite TDP-43 protein inclusions being originally identified in FTD cases, none of the FALS or SALS cases published to date show any evidence of overt dementia. However, two mutations in TARDBP, p.K263E and c.2076G>A in the 3′ UTR, have recently been found to be associated with individuals diagnosed with FTD [31, 32] . Further postmortem studies in cases with TARDBP mutations may elucidate differential pathologies in these cases compared to the range of TDP proteinopathies that show TDP-43 inclusions.
The familial p.Met337Val mutation has been identified in three other families with MND [20, 23, 28] . In FALS1 (Met337Val), a marked intra-familial variation in disease duration was observed, ranging from 9 months to 17 years. The average disease duration was 6.9 years compared to 5.5 years in the published detailed pedigree. Age at onset of symptoms is consistent with that previously published as is the classical ALS/MND phenotype observed. It is unclear whether the atypical phenotype manifesting in individual III.1 from this family is as a result of expression of TDP-43 mutation, as genetic testing has not been possible.
The familial p.Gly348Val mutation is a novel substitution, though p.Gly348Cys has been reported in four SALS cases from France, two cases in a family from Germany and in a large multigenerational family from Belgium [21, 22, 26, 27] . In FALS2, the phenotype observed was predominantly lower MN, with only subtle upper MN changes consisting of retained reflexes in the context of wasting. In the individual II.2, the disease initially resembled the flail arm variant. Bulbar function also remained intact in these individuals. In a previously reported mutation affecting this amino acid, it was also commented that there was a lack of bulbar symptoms [22] . A paucity of upper MN signs has been described with other mutations [21] . The age at onset and duration were comparable with other published pedigrees. The p.Gly287Ser mutation has been described previously in two SALS cases, one from France and the other from Italy [21, 28] . In our SALS1 case, the age of onset was 52 years, beginning in the limb. Whilst the Italian case also had spinal onset, at the age of 70 years, the French case presented with bulbar onset at 65 years. In all three cases, disease course has been relatively indolent with the affected individuals still living 5-7 years after symptom onset.
Therefore, taking into account all the published reports of ALS cases with TARDBP mutations, there does not appear to be any correlation between the age of onset, site of onset and disease duration of the patients with specific TARDBP mutations, taken either individually or as a group. This is a similar scenario to that observed in SOD1-related MND, where there is both inter-and intra-familial variation with the same mutation. Also, in line with SOD1, mutations in TARDBP are found in both familial and sporadic forms of the disease, with frequencies of TARDBP mutations from 0.6% to 6.5% for FALS and 0% to 5% for SALS, depending on the population sampled [20-26, 28, 33] . This compares with SOD1 mutation frequencies of 12-24% for FALS and 0-7% for SALS [4] .
Functional effects
All but one of the mutations identified to date reside in exon 6 of the TARDBP gene, which encodes for the end of the second RNA recognition motif (up to amino acid 262) and the entire glycine-rich domain of the TDP-43 protein (aa 274-413; Swiss-Prot Q13148 TARDBP_ HUMAN). This C-terminal region of the protein shows high levels of conservation (Fig. 5) , and the four mutations all affect highly conserved amino acid residues, which show conservation in mammals as well as chicken and zebrafish. The glycine-rich domain is involved in regulating alternative splicing, as demonstrated with cystic fibrosis transmembrane conductance regulator (CFTR) and apolipoprotein A-II (APOA2). This domain has also been shown to bind several hnRNP proteins involved in mRNA synthesis [14, 34, 35] . The C-terminal of TDP-43 has also been implicated as a transcriptional repressor. Thus, mutations in this region could have several deleterious effects on the function of the protein. Sreedharan has demonstrated that expression of the mutant p.M337V TDP-43 in the chick embryo results in the failure of normal limb and tail bud development [20] . In addition, both Kabashi and Rutherford show increased aggregation of detergent-insoluble mutant TDP-43 [21, 23] . Our bioinformatic analyses suggest that the two FALS and the novel SALS mutation are predicted to alter the function of the protein, whilst the p.Gly287Ser mutation, which has been found in an additional SALS case, is not predicted to have a major effect on the protein. However, QPCR of CDK6, which is repressed by TDP-43, shows an increase in expression in fibroblasts carrying the mutant proteins p.G287S, p.A321V and p.M337V. Therefore, we propose that these three mutants are unable to repress CDK6 as efficiently as the control fibroblasts.
In conclusion, mutations in TARDBP are found at a frequency of 5% for non-SOD1 FALS and 0.4% for SALS in a large cohort of MND cases from northern England. As found previously, these mutations reside in exon 6 of the gene, potentially interfering with the function of the glycine-rich domain. Analysis of clinical data suggests variability in the disease phenotype, though it is of note that the MND cases show no overt dementia symptoms.
